568 Shares in Stryker Co. (NYSE:SYK) Purchased by Kentucky Trust Co

Kentucky Trust Co acquired a new position in shares of Stryker Co. (NYSE:SYK) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 568 shares of the medical technology company’s stock, valued at approximately $205,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of SYK. Dunhill Financial LLC boosted its position in shares of Stryker by 94.9% in the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 37 shares in the last quarter. Darwin Wealth Management LLC purchased a new stake in shares of Stryker in the third quarter worth $36,000. Activest Wealth Management bought a new position in Stryker in the 4th quarter worth about $36,000. Crews Bank & Trust purchased a new stake in Stryker during the 4th quarter valued at about $39,000. Finally, Hara Capital LLC purchased a new position in Stryker in the third quarter worth about $42,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares in the company, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 5.90% of the stock is currently owned by insiders.

Stryker Stock Down 0.5 %

Shares of NYSE SYK opened at $390.52 on Wednesday. The stock has a market capitalization of $148.88 billion, a price-to-earnings ratio of 50.33, a P/E/G ratio of 2.98 and a beta of 0.96. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The firm’s 50-day moving average price is $377.28 and its 200-day moving average price is $365.59. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the previous year, the business earned $3.46 EPS. On average, equities research analysts anticipate that Stryker Co. will post 13.49 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.86%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s payout ratio is presently 43.30%.

Wall Street Analyst Weigh In

SYK has been the subject of several analyst reports. JPMorgan Chase & Co. raised their price target on shares of Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. Needham & Company LLC restated a “buy” rating and issued a $442.00 price target on shares of Stryker in a research note on Wednesday, January 29th. The Goldman Sachs Group increased their price objective on Stryker from $384.00 to $427.00 and gave the company a “neutral” rating in a research report on Thursday, January 30th. BTIG Research upped their target price on shares of Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Finally, Robert W. Baird lifted their price target on shares of Stryker from $378.00 to $405.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $420.68.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.